mojo, I don't understand this reasoning either. Shooting for a higher HR with a higher n (numbers of patients) makes me think that with a high enough n, the HR is going to be one, which would show no benefit for the treated group. There's something I'm missing here.
If Bavi really is efficacious, why wouldn't the phII HR carry over to the larger trial?
News 
Market Data 
Discover 
AI
